Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Kenneth R Miller who wrote (3005)	5/28/1998 7:07:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Re. ICOS's new drug. Kenneth, this hasn't been posted. Joe Kernen of CNBC mentioned this news item on The Edge, bascially read out the article, said he expected a move on the stock (ICOS) tomorrow. I think I've read about this drug IC351 in one of the articles about Viagra competitors, that it is going to be an expensive drug, but I just can't locate the article. Perhaps another poster has a better memory and can enlighten us on the competitive threat of ICOS's new drug.

To: Kenneth R Miller who wrote (3005)	5/28/1998 8:13:00 PM
From: LaVerne E. Olney	Read Replies (1) \| Respond to of 9523

From the ICOS web page icos.com IC351 status: phase 2 clinical trial primary indication: male erectile dysfunction Certain chemical signals increase blood flow to the tissues by raising the levels of cGMP in the smooth muscle cells lining the blood vessels. IC351, by blocking the cGMP-destroying enzyme PDE5, allows cGMP to accumulate thereby reinforcing the signal to increase blood flow. This certainly sounds like a Viagra analog. The key will be if, in fact, side effects are fewer, absorption is improved, and/or the physiologic effect enhanced.